As of yesterday's closing, Market Cap of RAP was $56m whereas we were at $19.8m.
Both are in the FDA process, one with a fantastic preliminary result and one needs to redo the trial due to certain procedural issues.
I would prefer to think that we are very undervalued compared to our peers.
Some here raise the possibility of a CR, I would hope the CR would be done at least at the MC of $50m or higher than our current $20m.
NTI Price at posting:
22.0¢ Sentiment: Buy Disclosure: Held
